Literature DB >> 21049704

Migraine: prophylactic treatment.

Rakesh Shukla1, Manish Sinh.   

Abstract

Prophylactic treatment constitutes an important aspect of migraine management and includes avoidance of trigger factors and life style advice followed by consideration of medications. The drugs of first choice are beta-blockers, flunarizine, topiramate, valproate and amitriptyline. Drugs of second choice with less efficacy and evidence are venlafaxine, gabapentin, naproxen, butterbur root, riboflavin and magnesium. Botulinum toxin type A has not yet been shown to be effective. The choice of prophylactic drugs would depend on efficacy, co-morbidity, side effects, availability and cost. Non-pharmacological treatments such as relaxation techniques, bio-feedback, cognitive behavioral therapy and acupuncture are supported by some evidence but require far more specialist time or technical devices. All the drugs used in migraine prophylaxis have been detected by serendipity. Drugs developed, in the future, on the basis of the current knowledge of pathophysiology will hopefully be more effective.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21049704

Source DB:  PubMed          Journal:  J Assoc Physicians India        ISSN: 0004-5772


  4 in total

1.  Preventive agents for migraine: focus on the antiepileptic drugs.

Authors:  R Shahien; K Beiruti
Journal:  J Cent Nerv Syst Dis       Date:  2012-02-26

2.  Propranolol: A 50-Year Historical Perspective.

Authors:  A V Srinivasan
Journal:  Ann Indian Acad Neurol       Date:  2019 Jan-Mar       Impact factor: 1.383

3.  Efficacy and Tolerability of Erenumab for Prevention of Episodic Migraine in India.

Authors:  Debashish Chowdhury; Jaydip R Chaudhuri; Pahari Ghosh; Rahul Kulkarni; Sumit Singh; Sneha Thakur; Anup V Thorat
Journal:  Ann Indian Acad Neurol       Date:  2022-06-09       Impact factor: 1.714

4.  Effects of Synergism of Mindfulness Practice Associated With Transcranial Direct-Current Stimulation in Chronic Migraine: Pilot, Randomized, Controlled, Double-Blind Clinical Trial.

Authors:  Luana Dias Santiago Pimenta; Elidianne Layanne Medeiros de Araújo; Joyce Poláine Dos Santos Silva; Jamyson Júnior França; Pedro Nascimento Araújo Brito; Ledycnarf Januário de Holanda; Ana Raquel Lindquist; Luiz Carlos Serramo Lopez; Suellen Marinho Andrade
Journal:  Front Hum Neurosci       Date:  2021-12-08       Impact factor: 3.169

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.